Pharmacological blockade of TRPM7, TRPV4 and TRPC6 channels and/or silent RNA (siRNA) driven downregulation of this channel expression may be a novel therapeutic approach for IPAH patients [37]. Here, TRPV4 is linked to idiopathic pulmonary arterial hypertension.